{"name":"Alcon","slug":"alcon","ticker":"ALC","exchange":"NYSE","domain":"alcon.com","description":"Alcon Inc. is a Swiss-American pharmaceutical and medical device company specializing in eye care products. Alcon is incorporated in the Canton of Fribourg, Switzerland, and its global headquarters are located in Geneva, but its main operational base is in Fort Worth, Texas, United States, where it employs about 4,500 people.","hq":"Geneva, Switzerland","founded":1945,"employees":"25000","ceo":"David Endicott","sector":"Ophthalmology / MedTech","stockPrice":63.82,"stockChange":0.38,"stockChangePercent":0.6,"marketCap":"$31.1B","metrics":{"revenue":10634000384,"revenueGrowth":9.4,"grossMargin":55.8,"rdSpend":0,"netIncome":819000000,"cash":1659000064,"dividendYield":0.57,"peRatio":38.2,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"1960-01-01","label":"Enlon-Plus first approved","drug":"Enlon-Plus","drugSlug":"lomotil","type":"approval","sentiment":"positive"},{"date":"1960-01-01","label":"Enlon-Plus first approved","drug":"Enlon-Plus","drugSlug":"atropin","type":"approval","sentiment":"positive"},{"date":"1974-01-01","label":"Cyclogyl first approved","drug":"Cyclogyl","drugSlug":"cyclopentolate","type":"approval","sentiment":"positive"},{"date":"2000-01-01","label":"Betaxon first approved","drug":"Betaxon","drugSlug":"levobetaxolol","type":"approval","sentiment":"positive"},{"date":"2005-01-01","label":"Tetracaine Hydrochloride first approved","drug":"Tetracaine Hydrochloride","drugSlug":"tetracaine","type":"approval","sentiment":"positive"},{"date":"2017-01-01","label":"Rhopressa first approved","drug":"Rhopressa","drugSlug":"netarsudil","type":"approval","sentiment":"positive"},{"date":"2025-01-01","label":"Tryptyr first approved","drug":"Tryptyr","drugSlug":"acoltremon","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Systane Ultra Lubricating Eye Drops patent cliff ($1.5B at risk)","drug":"Systane Ultra Lubricating Eye Drops","type":"patent_expiry","sentiment":"negative"},{"date":"2029-06-01","label":"Air Optix Aqua Contact Lenses patent cliff ($1.2B at risk)","drug":"Air Optix Aqua Contact Lenses","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":17,"colorKey":"oncology","drugs":[{"name":"Enlon-Plus","genericName":"Atropine Sulfate","slug":"lomotil","indication":"Perioperative Mydriasis","status":"marketed"},{"name":"Cyclogyl","genericName":"CYCLOPENTOLATE","slug":"cyclopentolate","indication":"Cycloplegia","status":"marketed"},{"name":"Enlon-Plus","genericName":"Atropin","slug":"atropin","indication":"Perioperative Mydriasis","status":"marketed"},{"name":"Fluticasone Propionate Nasal Spray, 50 mcg","genericName":"Fluticasone Propionate Nasal Spray, 50 mcg","slug":"fluticasone-propionate-nasal-spray-50-mcg","indication":"Other","status":"marketed"},{"name":"Maxidex","genericName":"Maxidex","slug":"maxidex","indication":"Other","status":"marketed"},{"name":"Timolol gel forming solution, 0.5%","genericName":"Timolol gel forming solution, 0.5%","slug":"timolol-gel-forming-solution-0-5","indication":"Other","status":"marketed"},{"name":"Triamcinolone Acetonide Injectable Suspension","genericName":"Triamcinolone Acetonide Injectable Suspension","slug":"triamcinolone-acetonide-injectable-suspension","indication":"Other","status":"marketed"},{"name":"Apraclonidine Hydrochloride Ophthalmic Solution","genericName":"Apraclonidine Hydrochloride Ophthalmic Solution","slug":"apraclonidine-hydrochloride-ophthalmic-solution","indication":"Other","status":"marketed"},{"name":"Brinzolamide 1% added to Travoprost 0.004%","genericName":"Brinzolamide 1% added to Travoprost 0.004%","slug":"brinzolamide-1-added-to-travoprost-0-004","indication":"Other","status":"marketed"},{"name":"Brinzolamide 1% ophthalmic suspension AZOPT®","genericName":"Brinzolamide 1% ophthalmic suspension AZOPT®","slug":"brinzolamide-1-ophthalmic-suspension-azopt","indication":"Other","status":"marketed"},{"name":"Habitual prostaglandin monotherapy","genericName":"Habitual prostaglandin monotherapy","slug":"habitual-prostaglandin-monotherapy","indication":"Other","status":"marketed"},{"name":"Healon","genericName":"Healon","slug":"healon","indication":"Other","status":"marketed"},{"name":"Nepafenac 0.1%","genericName":"Nepafenac 0.1%","slug":"nepafenac-0-1","indication":"Other","status":"marketed"},{"name":"Travacom","genericName":"Travacom","slug":"travacom","indication":"Other","status":"marketed"},{"name":"Travoprost 0.004% BAK-free","genericName":"Travoprost 0.004% BAK-free","slug":"travoprost-0-004-bak-free","indication":"Other","status":"marketed"},{"name":"brinzolamide 1.0%","genericName":"brinzolamide 1.0%","slug":"brinzolamide-1-0","indication":"Other","status":"marketed"},{"name":"quinolone","genericName":"quinolone","slug":"quinolone","indication":"Other","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"immunology","drugs":[{"name":"Azopt","genericName":"Azopt","slug":"azopt","indication":"Ocular hypertension","status":"marketed"},{"name":"Betaxon","genericName":"LEVOBETAXOLOL","slug":"levobetaxolol","indication":"Ocular hypertension","status":"marketed"},{"name":"Rhopressa","genericName":"NETARSUDIL","slug":"netarsudil","indication":"Ocular hypertension","status":"marketed"},{"name":"Subject's habitual PGA monotherapy","genericName":"Subject's habitual PGA monotherapy","slug":"subject-s-habitual-pga-monotherapy","indication":"Open-angle glaucoma","status":"marketed"},{"name":"Travatan","genericName":"Travatan","slug":"travatan","indication":"Ocular hypertension","status":"marketed"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"Tetracaine Hydrochloride","genericName":"TETRACAINE","slug":"tetracaine","indication":"Topical ophthalmic anesthesia","status":"marketed"},{"name":"Tryptyr","genericName":"ACOLTREMON","slug":"acoltremon","indication":"dry eye disease","status":"marketed"}]}],"pipeline":[{"name":"Enlon-Plus","genericName":"Atropine Sulfate","slug":"lomotil","phase":"marketed","mechanism":"Atropine antagonizes muscarine-like actions of acetylcholine through competitive antagonism at peripheral muscarinic receptors.","indications":["Perioperative Mydriasis"],"catalyst":""},{"name":"Cyclogyl","genericName":"CYCLOPENTOLATE","slug":"cyclopentolate","phase":"marketed","mechanism":"Muscarinic acetylcholine receptor M3","indications":["Cycloplegia","Dilated pupil","Perioperative Mydriasis"],"catalyst":""},{"name":"Enlon-Plus","genericName":"Atropin","slug":"atropin","phase":"marketed","mechanism":"Muscarinic acetylcholine receptor M3","indications":["Perioperative Mydriasis"],"catalyst":""},{"name":"Fluticasone Propionate Nasal Spray, 50 mcg","genericName":"Fluticasone Propionate Nasal Spray, 50 mcg","slug":"fluticasone-propionate-nasal-spray-50-mcg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Maxidex","genericName":"Maxidex","slug":"maxidex","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Timolol gel forming solution, 0.5%","genericName":"Timolol gel forming solution, 0.5%","slug":"timolol-gel-forming-solution-0-5","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Triamcinolone Acetonide Injectable Suspension","genericName":"Triamcinolone Acetonide Injectable Suspension","slug":"triamcinolone-acetonide-injectable-suspension","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Apraclonidine Hydrochloride Ophthalmic Solution","genericName":"Apraclonidine Hydrochloride Ophthalmic Solution","slug":"apraclonidine-hydrochloride-ophthalmic-solution","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Azopt","genericName":"Azopt","slug":"azopt","phase":"marketed","mechanism":"Carbonic anhydrase 1, Carbonic anhydrase 12, Carbonic anhydrase 13","indications":["Ocular hypertension","Open-angle glaucoma"],"catalyst":""},{"name":"Betaxon","genericName":"LEVOBETAXOLOL","slug":"levobetaxolol","phase":"marketed","mechanism":"Beta-1 adrenergic receptor","indications":["Ocular hypertension","Open-angle glaucoma"],"catalyst":""},{"name":"Brinzolamide 1% added to Travoprost 0.004%","genericName":"Brinzolamide 1% added to Travoprost 0.004%","slug":"brinzolamide-1-added-to-travoprost-0-004","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Brinzolamide 1% ophthalmic suspension AZOPT®","genericName":"Brinzolamide 1% ophthalmic suspension AZOPT®","slug":"brinzolamide-1-ophthalmic-suspension-azopt","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Habitual prostaglandin monotherapy","genericName":"Habitual prostaglandin monotherapy","slug":"habitual-prostaglandin-monotherapy","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Healon","genericName":"Healon","slug":"healon","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Nepafenac 0.1%","genericName":"Nepafenac 0.1%","slug":"nepafenac-0-1","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Rhopressa","genericName":"NETARSUDIL","slug":"netarsudil","phase":"marketed","mechanism":"Netarsudil reduces intraocular pressure by increasing aqueous humor outflow through the trabecular meshwork.","indications":["Ocular hypertension","Open-angle glaucoma"],"catalyst":""},{"name":"Subject's habitual PGA monotherapy","genericName":"Subject's habitual PGA monotherapy","slug":"subject-s-habitual-pga-monotherapy","phase":"marketed","mechanism":"PGA (prostaglandin analog) monotherapy reduces intraocular pressure by increasing uveoscleral outflow of aqueous humor.","indications":["Open-angle glaucoma","Ocular hypertension"],"catalyst":""},{"name":"Tetracaine Hydrochloride","genericName":"TETRACAINE","slug":"tetracaine","phase":"marketed","mechanism":"Tetracaine Hydrochloride works by blocking sodium channels in nerve cells to prevent pain signals from being transmitted.","indications":["Topical ophthalmic anesthesia"],"catalyst":""},{"name":"Travacom","genericName":"Travacom","slug":"travacom","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Travatan","genericName":"Travatan","slug":"travatan","phase":"marketed","mechanism":"Prostaglandin E2 receptor EP3 subtype, Prostaglandin F2-alpha receptor","indications":["Ocular hypertension","Open-angle glaucoma"],"catalyst":""},{"name":"Travoprost 0.004% BAK-free","genericName":"Travoprost 0.004% BAK-free","slug":"travoprost-0-004-bak-free","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Tryptyr","genericName":"ACOLTREMON","slug":"acoltremon","phase":"marketed","mechanism":"Tryptyr works by modulating the function of the lacrimal gland to increase tear production.","indications":["dry eye disease","dry eye disease"],"catalyst":""},{"name":"brinzolamide 1.0%","genericName":"brinzolamide 1.0%","slug":"brinzolamide-1-0","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"quinolone","genericName":"quinolone","slug":"quinolone","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2023-02-01","type":"earnings","headline":"Alcon Reports Fourth-Quarter and Full-Year 2022 Results","summary":"Alcon reported its fourth-quarter and full-year 2022 results, with net sales of $7.4 billion and adjusted EBITDA of $2.4 billion.","drugName":"","sentiment":"neutral"},{"date":"2022-05-31","type":"deal","headline":"Novartis Completes Spin-Off of Alcon","summary":"Novartis completed the spin-off of Alcon, making it an independent publicly traded company.","drugName":"","sentiment":"positive"},{"date":"2021-12-15","type":"regulatory","headline":"Alcon Receives FDA Approval for Systane Ultra Lubricating Eye Drops","summary":"Alcon received FDA approval for Systane Ultra Lubricating Eye Drops, a new treatment for dry eye disease.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE5BWGl0cjhPSHJ3REU2a3dIanlmbmVMT0xrT1hOSXJ6YTQyZHhFWTM5NDFYR3NDNG4tRE5TWXFfbG9ITVp5Y3dEXzc0aFVkRG1vUk1LMi13dkExREZVX1E?oc=5","date":"2026-04-02","type":"pipeline","source":"ChartMill","summary":"ALC Stock Price, Quote & Chart | ALCON INC (NYSE:ALC) - ChartMill","headline":"ALC Stock Price, Quote & Chart | ALCON INC (NYSE:ALC)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxOTlo2NXBwNjQ3SkdRYnZZQ0M0WEtVMFRIUGdnUjFHU1d2SmVKZmhBa01RWHc5ZUxqd3lPMXBDcU1kVnhTUFJ3Vloza1BNQ05ZMk1OVHZWN29nT0IwZkpsc0h2cWxIeTg1cEFHOTc0ZFluSDI1N0F6NGlMN2o5cC0wdFRQLTRHMHpKMXAyQ1VtVkF0di1sNnc?oc=5","date":"2025-11-14","type":"pipeline","source":"Seeking Alpha","summary":"Alcon: Some Premium Coming Out Of This Quality Play (ALC) - Seeking Alpha","headline":"Alcon: Some Premium Coming Out Of This Quality Play (ALC)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxNZklaLWNWWGIzaTNETHlVb01HZ1lXTEp2aFgyME9Vd0VVeDNvbm5xdnZWNHFTNXZUbUFHTkZ5OVhPTktVUktXdnNfVENJakpOZGdidHBuRUhnTDNrRmtHYWNSQkxxUm41bk1YUENES251cXR6Z0xQbktGalhaVFJWM0xEY0lwOEJFVVE?oc=5","date":"2025-09-24","type":"pipeline","source":"The Business Journals","summary":"Alcon considers moving manufacturing lines to Fort Worth from Europe, creating hundreds of jobs - The Business Journals","headline":"Alcon considers moving manufacturing lines to Fort Worth from Europe, creating hundreds of jobs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxObFYzaFk1ZjdWYk1HVlFJczRJRlcyWmxKcXZXcV9ZQ3Vva1JwYXpwRjJJTENBSHJnTmRTQWE2djIzbHZKRW5wNWs2YVVoMXVOTGFVT1Zzc3dHVmdTQkhNNldORkdFNWJxYlFwekk1eTZZeERCc1Y3TzliTUFTaThoRg?oc=5","date":"2025-09-19","type":"pipeline","source":"Yahoo Finance","summary":"Is it a Prudent Move to Retain ALC Stock in Your Portfolio Now? - Yahoo Finance","headline":"Is it a Prudent Move to Retain ALC Stock in Your Portfolio Now?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxOV1U1WFpNUzQwcXhmWDFYNXpKVHROd2FHejhVdlZmOEtaYjVOalhSYTJXMGlISjY0RVhFUlZucEVPQ1pjaUw3QmdjZWN2Rm1Mc2U0RjZ6ZjVJekxsTGJYMHZ6SlM0NVpmWmJUYWd5b1c2a0Y3TlFqWVE5YkZuX1c4OEU1OEduOVRTRFB6aHRRQQ?oc=5","date":"2025-05-30","type":"regulatory","source":"The Pharma Letter","summary":"Alcon gains FDA approval of Tryptyr in DED - The Pharma Letter","headline":"Alcon gains FDA approval of Tryptyr in DED","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiogJBVV95cUxPT012aE9KcDlxcmRINWIwZGxFdl95NDc0TmFqbDR5N2lkeHpOMHh2VW9jaXNqNHZoN0FWc2tPeFZSM2J6dzRUMlJkal9JTmFiS3ZfcHZ4STBsdkpzYWwzVExtbUhRb0dUZXBUM2FxaG1BcXJNcG5hSVB4dFBSNTFGLXhaUGZKOGtWWUhnbGJyMHFWcjcwVU9nODFoX3dYZTBEX0dKSFRrRG9sTHY4Q2tFOUpjcWhvSThSN3V3cUZ2cDlaY3BwT2p6MVkwNXZKcnNCT0U0Tjh0a2oyeGdzdG5RMWRrZXlyOFFSOURGTVZVc0Nia3hsVDAwbjRIWjhNZ3BCYUt2TFNtNW03YnJIdnlxNzVfM1o5ODJOZGZqRU1pN0w4UQ?oc=5","date":"2025-05-28","type":"regulatory","source":"Business Wire","summary":"Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease - Business Wire","headline":"Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Sympt","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNLWlZaVZtWVRmaWkxaG14YnNORV9KcE4yUkhMa1dwWlBoaWRnbF8tLWJlbi1jR0hrdERhNXY4aU93QXJyZG05T29pdU1tRG1KOFY2dDhvNklFNFktWXJXTHBWZTBsSWFZYWlvTEljMVVhNFpJQndsTDVVYzBWQnA3QXBHTHN0Wi1jTlhj?oc=5","date":"2025-02-26","type":"pipeline","source":"SEC.gov","summary":"alc-20241231 - SEC.gov","headline":"alc-20241231","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiT0FVX3lxTE1aRVk2MXBIc1d6N0dLR0FMOW9Ud0QtRTdrVXlfQ0ozc2pqOFJsRktkZ3JGOUdQelJmS2l5TGNRMzVzQUctdG94TFNFclVVM1k?oc=5","date":"2024-02-28","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxPeElhUl92Y2tuSi15S2EzXzkzNVpqTExVcjNUWEMtcDZrNGVseTJTSVQ4am1ZYUh2TUFUaTVkQ3JUbmxNX2NXNERHLVkyWlRSTlZnOTJ5bmgxX21tb0tVMEhpajNTUzNIRGEwdlFRNFpFQjJ5N1pWdXctd2JJdFQ1S0k4Q1BlTDBlaFgwcG5yU2dROWtkQ2c?oc=5","date":"2022-11-22","type":"pipeline","source":"citybiz","summary":"Alcon Completes Acquisition of Aerie Pharmaceuticals - citybiz","headline":"Alcon Completes Acquisition of Aerie Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxNeXVKUVBYYmNBTWFsbG56RlNYVC13TlJaSGdxWEJBX3FpNGZxOEtKaWplQ2tsMGJNQU8zNE5vYm01YUdvaE1iR2RWTkdnVXBRcVlORXRhYlpPVUVtYW00Rjd2UGxjYXNkY1pVQ01NenNFSnpkeFV4QWI2Z0Z1Q2NOSDNCSDQ5WGJMcWtvZEQyZFZTWk9zSzhyQ0NiUUxYYlZWbVI5ekQwdVdmOGE2ZW9BdFd5ai1yRkJVS3hja1VVRU4yS0lOSldpVEw3a1NCbXhKcnF0aml3?oc=5","date":"2022-08-24","type":"deal","source":"VisionMonday.com","summary":"Alcon to Acquire Aerie Pharmaceuticals, Inc., Enhancing its Ophthalmic Pharmaceutical Portfolio - VisionMonday.com","headline":"Alcon to Acquire Aerie Pharmaceuticals, Inc., Enhancing its Ophthalmic Pharmaceutical Portfolio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxPbGVSc1UzX083V3pZcnVYaDU1SDNmOWwydlFqQWVVc01qOVNaNmszbTRzNHJ2RHZQQThkTzNFLVZNd3FvdFJiVzc4bldXMmtTUEZCcmhxTml0SUFPU08zSjNNNkhtUnJycG9ENTNJTUNJdHlKX0NBaVczeGt0TUpwQ0pmZ2ltTDQ2UEJB?oc=5","date":"2022-08-23","type":"deal","source":"Barron's","summary":"Aerie Pharmaceuticals Stock Surges as Alcon to Buy Eye Care Firm in $770 Million Deal - Barron's","headline":"Aerie Pharmaceuticals Stock Surges as Alcon to Buy Eye Care Firm in $770 Million Deal - Barron's","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxQQVlQcnBiTmVvWmZQenl5ZW16cW0tV1dwMjhoSEFPQWFJV1lveDZpeUViXy13UElNVENTeWk1VEpzVEpqSlBSM3JzSEtGeG91TjdRUFV1cEMwMEdsOEd6UXl4Z2hLVU1NREN2S3piaGFXdkF1bTBsc2d5WEExVFJnWDU0d0l2anlCX1NvWjlCeHB3MmtYVy1LblNiWTVCR0h0TE1iVmFhbw?oc=5","date":"2019-04-09","type":"regulatory","source":"BioPharma Dive","summary":"Alcon spin-out marks step in Novartis plan to remake business - BioPharma Dive","headline":"Alcon spin-out marks step in Novartis plan to remake business","sentiment":"neutral"}],"patents":[{"drugName":"Systane Ultra Lubricating Eye Drops","drugSlug":"systane-ultra","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1500000000},{"drugName":"Air Optix Aqua Contact Lenses","drugSlug":"air-optix-aqua","patentNumber":"","type":"Patent Cliff","expiryDate":"2029-06-01","territory":"US","annualRevenue":1200000000}],"drugCount":24,"phaseCounts":{"marketed":23,"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Johnson & Johnson","Bausch Health","Abbott Laboratories"],"therapeuticFocus":["Ophthalmology","Eye Care"],"financials":{"source":"yahoo_finance","revenue":10401000000,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":10401000000},{"period":"2024-12-31","value":9911000000},{"period":"2023-12-31","value":9455000000},{"period":"2022-12-31","value":8717000000}],"grossProfit":5745000000,"grossProfitHistory":[{"period":"2025-12-31","value":5745000000},{"period":"2024-12-31","value":5512000000},{"period":"2023-12-31","value":5247000000},{"period":"2022-12-31","value":4748000000}],"rdSpend":990000000,"rdSpendHistory":[{"period":"2025-12-31","value":990000000},{"period":"2024-12-31","value":876000000},{"period":"2023-12-31","value":828000000},{"period":"2022-12-31","value":702000000}],"sgaSpend":3449000000,"operatingIncome":1360000000,"operatingIncomeHistory":[{"period":"2025-12-31","value":1360000000},{"period":"2024-12-31","value":1413000000},{"period":"2023-12-31","value":1039000000},{"period":"2022-12-31","value":672000000}],"netIncome":980000000,"netIncomeHistory":[{"period":"2025-12-31","value":980000000},{"period":"2024-12-31","value":1018000000},{"period":"2023-12-31","value":974000000},{"period":"2022-12-31","value":335000000}],"eps":1.98,"epsHistory":[{"period":"2025-12-31","value":1.98},{"period":"2024-12-31","value":2.05},{"period":"2023-12-31","value":1.96},{"period":"2022-12-31","value":0.68}],"cash":1676000000,"cashHistory":[{"period":"2024-12-31","value":1676000000},{"period":"2023-12-31","value":1094000000},{"period":"2022-12-31","value":980000000},{"period":"2021-12-31","value":1575000000}],"totalAssets":31555000000,"totalLiabilities":31555000000,"totalDebt":509000000,"equity":22014000000,"operatingCashflow":2271000000,"operatingCashflowHistory":[{"period":"2025-12-31","value":2271000000},{"period":"2024-12-31","value":2077000000},{"period":"2023-12-31","value":1388000000},{"period":"2022-12-31","value":1217000000}],"capex":-663000000,"capexHistory":[{"period":"2025-12-31","value":-663000000},{"period":"2024-12-31","value":-670000000},{"period":"2023-12-31","value":-851000000},{"period":"2022-12-31","value":-745000000}],"freeCashflow":1608000000,"dividendsPaid":-166000000,"buybacks":-676000000,"employees":25000,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":882000000,"ebit":292000000,"ebitda":614000000,"period":"2026-03-31","revenue":2706000000,"epsBasic":0.39,"netIncome":189000000,"rdExpense":245000000,"epsDiluted":0.39,"grossProfit":1525000000,"operatingIncome":292000000},{"sga":901000000,"ebit":317000000,"ebitda":793000000,"period":"2025-12-31","revenue":2718000000,"epsBasic":0.44,"netIncome":217000000,"rdExpense":273000000,"epsDiluted":0.44,"grossProfit":1516000000,"operatingIncome":313000000},{"sga":865000000,"ebit":334000000,"ebitda":521000000,"period":"2025-09-30","revenue":2614000000,"epsBasic":0.48,"netIncome":237000000,"rdExpense":250000000,"epsDiluted":0.48,"grossProfit":1458000000,"operatingIncome":332000000},{"sga":870000000,"ebit":250000000,"ebitda":612000000,"period":"2025-06-30","revenue":2596000000,"epsBasic":0.36,"netIncome":176000000,"rdExpense":245000000,"epsDiluted":0.35,"grossProfit":1388000000,"operatingIncome":247000000},{"sga":813000000,"ebit":463000000,"ebitda":773000000,"period":"2025-03-31","revenue":2473000000,"epsBasic":0.71,"netIncome":350000000,"rdExpense":222000000,"epsDiluted":0.7,"grossProfit":1383000000,"operatingIncome":468000000}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":63.82,"previousClose":63.44,"fiftyTwoWeekHigh":92.55,"fiftyTwoWeekLow":61.84,"fiftyTwoWeekRange":"61.835 - 92.55","fiftyDayAverage":75.39,"twoHundredDayAverage":78.39,"beta":0.7,"enterpriseValue":34543689728,"forwardPE":16.1,"priceToBook":1.41,"priceToSales":2.93,"enterpriseToRevenue":3.25,"enterpriseToEbitda":15.25,"pegRatio":1.39,"ebitda":2264999936,"ebitdaMargin":21.3,"freeCashflow":1191750016,"operatingCashflow":2304999936,"totalDebt":5262000128,"debtToEquity":23.8,"currentRatio":2.2,"returnOnAssets":2.5,"returnOnEquity":3.7,"analystRating":"1.6 - Buy","recommendationKey":"buy","numberOfAnalysts":16,"targetMeanPrice":88.21,"targetHighPrice":113,"targetLowPrice":66,"dividendRate":0.36,"payoutRatio":0.2,"fiveYearAvgDividendYield":0.29,"exDividendDate":1778025600,"insiderHeldPercent":0.2,"institutionHeldPercent":67.6,"sharesOutstanding":487700000,"floatShares":486373456,"sharesShort":5146734,"shortRatio":3.81,"shortPercentOfFloat":1.1,"epsTrailing":1.67,"epsForward":3.97,"revenuePerShare":21.65,"bookValue":45.38,"officers":[{"age":60,"name":"Mr. David J. Endicott","title":"CEO & Director"},{"age":58,"name":"Mr. Timothy C. Stonesifer","title":"Senior VP & CFO"},{"age":54,"name":"Mr. Ian  Bell","title":"Senior VP & COO"},{"age":null,"name":"Margaret  Buckley","title":"Chief Accounting Officer"},{"age":null,"name":"Dr. Franck  Leveiller Ph.D.","title":"SVP of Global Research & Development and Chief Scientific Officer"},{"age":null,"name":"Mr. Muru  Murugappan","title":"Senior VP and Chief Information & Transformation Officer"},{"age":59,"name":"Mr. Royce R. Bedward J.D.","title":"Senior VP, General Counsel & Corporate Secretary"},{"age":50,"name":"Ms. Kimberly  Martin","title":"Senior VP and Chief HR & Corporate Communications"}],"industry":"Medical Instruments & Supplies","irWebsite":"","website":"https://www.alcon.com","phone":"41 589 112 110"}}